National Immunotherapy Cancer Research Foundation, Inc. – Trademark Portfolio
Entity Type: 03
National Immunotherapy Cancer Research Foundation, Inc. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 36 (Insurance & Financial) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include NATIONAL IMMUNOTHERAPY CANCER RESEARCH FOUNDATION, INC.. The owner is based in Flemington, NJ.
PO Box 272
Flemington, NJ 08822
Showing of trademarks Trademarks
Trademark Classifications
National Immunotherapy Cancer Research Foundation, Inc.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.
Insurance; financial affairs; monetary affairs; real estate affairs
Frequently Asked Questions
How many trademarks does National Immunotherapy Cancer Research Foundation, Inc. have?
National Immunotherapy Cancer Research Foundation, Inc. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.
What trademark classes does National Immunotherapy Cancer Research Foundation, Inc. file in?
National Immunotherapy Cancer Research Foundation, Inc. files trademarks across 1 Nice Classification class. The most active classes are Class 36 (Insurance & Financial). Class 36 covers insurance; financial affairs; monetary affairs; real estate affairs.
What are National Immunotherapy Cancer Research Foundation, Inc.'s most well-known trademarks?
National Immunotherapy Cancer Research Foundation, Inc.'s registered trademark portfolio includes well-known marks such as NATIONAL IMMUNOTHERAPY CANCER RESEARCH FOUNDATION, INC.. These are among 1 currently registered trademark in the portfolio.
What is National Immunotherapy Cancer Research Foundation, Inc.'s trademark registration success rate?
National Immunotherapy Cancer Research Foundation, Inc. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.